Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation

Clinicaltrials.gov ID: NCT07203482
db-list-check Status RECRUITING
b-loader Phase
b-people Age 40 - 95 Years
b-bullseye-arrow Enrollments 300

Conditions

Prostate Cancer

Summary

Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this research database is to prospectively collect data to assess treatment related complications, oncologic outcomes and urinary/sexual function, and identify predictors of complications, oncological control and functional outcomes after Hhigh-intensity focused ultrasound (HIFU) ablation of prostate cancer with the intent to guide further research and improve patient care. We will include subjects who will have a HIFU procedure performed from all Sub-Investigators included in the study.

Locations

2 locations Found with status Recruiting

Status

  • RECRUITING

Central Contacts

Principal Investigator

  • James Wysock, MD

Status

  • RECRUITING

Central Contacts

Principal Investigator

  • James Wysock, MD

Eligibility Criteria

Inclusion Criteria:

* Males, ages 40-95
* Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
* Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) that select focal HIFU prostate ablation as their treatment option will be offered inclusion into this prospective data collection research database.
* Patients who have early (Gleason 6 or 7), low grade cancer that is confined to the prostate.
* Willing and able to provide consent.

Exclusion Criteria:

* Patients that are not diagnosed with prostate cancer.
* Patients that are diagnosed with clinically localized prostate cancer, but select other tratment options as their desired treatment.
* Patients that are not willing or are not able to give consent.

Study Plan

Prostate Cancer Patients Scheduled for HIFU Procedure

Participants will be actively followed up for the first 3 years. After that once a year for life, unless they withdraw from the study or no longer seek standard of care at NYU Langone Health.

Outcome Measures

Primary Outcome Measures

Change in Prostate-Specific Antigen (PSA) Levels

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Change in Urinary Function Score

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Change in Urinary Continence Score

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Change in Sexual Function Score

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Change in Ejaculatory Function Score

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Change in Sexual Health Inventory for Men (SHIM) Score

Time Frame: Baseline (pre-HIFU ablation procedure), Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Decision Regret Score

Time Frame: Month 3, Month 6, Month 12, Month 18, Month 24, Month 30, Month 48, Month 60

Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Imaging

Time Frame: Up to Month 60

Number of Participants with New Lesions in the Non-Treated Prostate on Post-Treatment Imaging

Time Frame: Up to Month 60

Number of Participants with Persistence or Recurrence of Cancer within the Treatment Zone on Post-Treatment Prostate Biopsy

Time Frame: Up to Month 60

Number of Participants with New Lesions in the Non-Treated Prostate on Post-Treatment Prostate Biopsy

Time Frame: Up to Month 60

Timeline

  • Last Updated
    October 2, 2025
  • Start Date
    October 2, 2025
  • Today
    March 14, 2026
  • Completion Date ( Estimated )
    December 31, 2050

Similar Trials

light-list-check RECRUITING light-blue-people 18 - 80 Years
light-list-check RECRUITING light-blue-people 40 - 90 Years
light-list-check RECRUITING light-blue-people ≥ 18 Years